

Isabel Gonzalez-Alvarez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3202185/publications.pdf>

Version: 2024-02-01

105
papers

2,484
citations

201385

27
h-index

264894

42
g-index

113
all docs

113
docs citations

113
times ranked

3240
citing authors

#	ARTICLE	IF	CITATIONS
1	Integration of In Silico, In Vitro and In Situ Tools for the Preformulation and Characterization of a Novel Cardio-Neuroprotective Compound during the Early Stages of Drug Development. <i>Pharmaceutics</i> , 2022, 14, 182.	2.0	0
2	An Innovative Formulation Based on Nanostructured Lipid Carriers for Imatinib Delivery: Pre-Formulation, Cellular Uptake and Cytotoxicity Studies. <i>Nanomaterials</i> , 2022, 12, 250.	1.9	7
3	Exploring the Predictive Power of the <i>In Situ</i> Perfusion Technique towards Drug Absorption: Theory, Practice, and Applications. <i>Molecular Pharmaceutics</i> , 2022, 19, 749-762.	2.3	3
4	Effect of excipients on oral absorption process according to the different gastrointestinal segments. Expert Opinion on Drug Delivery, 2021, 18, 1005-1024.	2.4	8
5	Two-step in vitro-in vivo correlations: Deconvolution and convolution methods, which one gives the best predictability? Comparison with one-step approach. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2021, 158, 185-197.	2.0	6
6	Regional Intestinal Drug Absorption: Biopharmaceutics and Drug Formulation. <i>Pharmaceutics</i> , 2021, 13, 272.	2.0	5
7	An In Vivo Predictive Dissolution Methodology (iPD Methodology) with a BCS Class IIb Drug Can Predict the In Vivo Bioequivalence Results: Etoricoxib Products. <i>Pharmaceutics</i> , 2021, 13, 507.	2.0	7
8	Eremantholide C from aerial parts of <i>Lychnophora trichocarpha</i> , as drug candidate: fraction absorbed prediction in humans and BCS permeability class determination. <i>DARU, Journal of Pharmaceutical Sciences</i> , 2021, 29, 195-203.	0.9	1
9	One and Two-Step In Vitro-In Vivo Correlations Based on USP IV Dynamic Dissolution Applied to Four Sodium Montelukast Products. <i>Pharmaceutics</i> , 2021, 13, 690.	2.0	2
10	In vitro model for predicting the access and distribution of drugs in the brain using hCMEC/D3 cells. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2021, 163, 120-126.	2.0	19
11	Lactose-Gated Mesoporous Silica Particles for Intestinal Controlled Delivery of Essential Oil Components: An In Vitro and In Vivo Study. <i>Pharmaceutics</i> , 2021, 13, 982.	2.0	5
12	A differential equation based modelling approach to predict supersaturation and in vivo absorption from in vitro dissolution-absorption system (idas2) data. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2021, 165, 1-12.	2.0	9
13	Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Brain Levels of Drug in Rat. <i>Pharmaceutics</i> , 2021, 13, 1402.	2.0	4
14	pH-Dependent Molecular Gate Mesoporous Microparticles for Biological Control of <i>Giardia intestinalis</i> . <i>Pharmaceutics</i> , 2021, 13, 94.	2.0	3
15	Global testing of a consensus solubility assessment to enhance robustness of the WHO biopharmaceutical classification system. <i>ADMET and DMPK</i> , 2021, 9, 23-39.	1.1	7
16	New In Vitro Methodology for Kinetics Distribution Prediction in the Brain. An Additional Step towards an Animal-Free Approach. <i>Animals</i> , 2021, 11, 3521.	1.0	4
17	Surfactant-Triggered Molecular Gate Tested on Different Mesoporous Silica Supports for Gastrointestinal Controlled Delivery. <i>Nanomaterials</i> , 2020, 10, 1290.	1.9	8
18	Biomimetic Artificial Membrane Permeability Assay over Franz Cell Apparatus Using BCS Model Drugs. <i>Pharmaceutics</i> , 2020, 12, 988.	2.0	12

#	ARTICLE	IF	CITATIONS
19	New Insights of Oral Colonic Drug Delivery Systems for Inflammatory Bowel Disease Therapy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6502.	1.8	43
20	Effect of Common Excipients on Intestinal Drug Absorption in Wistar Rats. <i>Molecular Pharmaceutics</i> , 2020, 17, 2310-2318.	2.3	8
21	Effect of thickener on disintegration, dissolution and permeability of common drug products for elderly patients. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2020, 153, 168-176.	2.0	6
22	Recent developments in cancer therapy and diagnosis. <i>Journal of Pharmaceutical Investigation</i> , 2020, 50, 349-361.	2.7	35
23	Differences in the clinical management of women and men after detection of a solitary pulmonary nodule in clinical practice. <i>European Radiology</i> , 2020, 30, 4390-4397.	2.3	6
24	Segmental-Dependent Solubility and Permeability as Key Factors Guiding Controlled Release Drug Product Development. <i>Pharmaceutics</i> , 2020, 12, 295.	2.0	15
25	In Vivo Predictive Dissolution (IPD) for Carbamazepine Formulations: Additional Evidence Regarding a Biopredictive Dissolution Medium. <i>Pharmaceutics</i> , 2020, 12, 558.	2.0	7
26	Candesartan Cilixetil In Vitro [®] In Vivo Correlation: Predictive Dissolution as a Development Tool. <i>Pharmaceutics</i> , 2020, 12, 633.	2.0	17
27	Oral controlled release dosage forms: dissolution versus diffusion. <i>Expert Opinion on Drug Delivery</i> , 2020, 17, 791-803.	2.4	13
28	Availability of Authorizations from EMA and FDA for Age-Appropriate Medicines Contained in the WHO Essential Medicines List for Children 2019. <i>Pharmaceutics</i> , 2020, 12, 316.	2.0	17
29	Classification of WHO Essential Oral Medicines for Children Applying a Provisional Pediatric Biopharmaceutics Classification System. <i>Pharmaceutics</i> , 2019, 11, 567.	2.0	27
30	Double Drug Delivery Using Capped Mesoporous Silica Microparticles for the Effective Treatment of Inflammatory Bowel Disease. <i>Molecular Pharmaceutics</i> , 2019, 16, 2418-2429.	2.3	18
31	Exploring Bioequivalence of Dexketoprofen Trometamol Drug Products with the Gastrointestinal Simulator (GIS) and Precipitation Pathways Analyses. <i>Pharmaceutics</i> , 2019, 11, 122.	2.0	17
32	Intestinal Permeability Study of Clinically Relevant Formulations of Silibinin in Caco-2 Cell Monolayers. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1606.	1.8	32
33	Investigation to Explain Bioequivalence Failure in Pravastatin Immediate-Release Products. <i>Pharmaceutics</i> , 2019, 11, 663.	2.0	10
34	Ion-pair approach coupled with nanoparticle formation to increase bioavailability of a low permeability charged drug. <i>International Journal of Pharmaceutics</i> , 2019, 557, 36-42.	2.6	11
35	Impact on intestinal permeability of pediatric hyperosmolar formulations after dilution: Studies with rat perfusion method. <i>International Journal of Pharmaceutics</i> , 2019, 557, 154-161.	2.6	6
36	Covalently crosslinked organophosphorous derivatives-chitosan hydrogel as a drug delivery system for oral administration of camptothecin. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2019, 136, 174-183.	2.0	45

#	ARTICLE	IF	CITATIONS
37	Closed-Loop Doluisio (Colon, Small Intestine) and Single-Pass Intestinal Perfusion (Colon, Jejunum) in Ratâ€”Biophysical Model and Predictions Based on Caco-2. <i>Pharmaceutical Research</i> , 2018, 35, 2.	1.7	23
38	Ionic Hydrogel Based on Chitosan Cross-Linked with 6-Phosphogluconic Trisodium Salt as a Drug Delivery System. <i>Biomacromolecules</i> , 2018, 19, 1294-1304.	2.6	41
39	Evaluation and optimized selection of supersaturating drug delivery systems of posaconazole (BCS) Tj ETQq1 1 0.784314 rgBT /Overl <i>Journal of Pharmaceutical Sciences</i> , 2018, 115, 258-269.	1.9	43
40	PLGA nanoparticles are effective to control the colonic release and absorption on ibuprofen. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 115, 119-125.	1.9	25
41	Giardiasis: Characteristics, Pathogenesis and New Insights About Treatment. <i>Current Topics in Medicinal Chemistry</i> , 2018, 18, 1287-1303.	1.0	58
42	Long-Circulating Hyaluronan-Based Nanohydrogels as Carriers of Hydrophobic Drugs. <i>Pharmaceutics</i> , 2018, 10, 213.	2.0	4
43	Determination of intestinal permeability using in situ perfusion model in rats: Challenges and advantages to BCS classification applied to digoxin. <i>International Journal of Pharmaceutics</i> , 2018, 551, 148-157.	2.6	18
44	Preclinical models for colonic absorption, application to controlled release formulation development. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2018, 130, 247-259.	2.0	10
45	In Vitro Dissolution as a Tool for Formulation Selection: Telmisartan Two-Step IVIVC. <i>Molecular Pharmaceutics</i> , 2018, 15, 2307-2315.	2.3	26
46	Smart gated magnetic silica mesoporous particles for targeted colon drug delivery: New approaches for inflammatory bowel diseases treatment. <i>Journal of Controlled Release</i> , 2018, 281, 58-69.	4.8	39
47	Biopharmaceutical optimization in neglected diseases for paediatric patients by applying the provisional paediatric biopharmaceutical classification system. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 2231-2241.	1.1	18
48	Usefulness of Caco-2/HT29-MTX and Caco-2/HT29-MTX/Raji B Coculture Models To Predict Intestinal and Colonic Permeability Compared to Caco-2 Monoculture. <i>Molecular Pharmaceutics</i> , 2017, 14, 1264-1270.	2.3	123
49	Investigating drug absorption from the colon: Single-pass vs. Doluisio approaches to in-situ rat large-intestinal perfusion. <i>International Journal of Pharmaceutics</i> , 2017, 527, 135-141.	2.6	28
50	Phenolic compounds in rosemary as potential source of bioactive compounds against colorectal cancer: In situ absorption and metabolism study. <i>Journal of Functional Foods</i> , 2017, 33, 202-210.	1.6	30
51	Gated Mesoporous Silica Nanocarriers for a â€œTwo-Stepâ€ Targeted System to Colonic Tissue. <i>Molecular Pharmaceutics</i> , 2017, 14, 4442-4453.	2.3	18
52	Comparison of segmental-dependent permeability in human and in situ perfusion model in rat. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 107, 191-196.	1.9	21
53	Enhancing Oral Absorption of ¹² -Lapachone: Progress Till Date. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2017, 42, 1-10.	0.6	6
54	Evaluation of the intestinal permeability of rosemary (<i>Rosmarinus officinalis</i> L.) extract polyphenols and terpenoids in Caco-2 cell monolayers. <i>PLoS ONE</i> , 2017, 12, e0172063.	1.1	35

#	ARTICLE	IF	CITATIONS
55	Segmental-dependent permeability throughout the small intestine following oral drug administration: Single-pass vs. Doluisio approach to in-situ rat perfusion. <i>International Journal of Pharmaceutics</i> , 2016, 515, 201-208.	2.6	46
56	Development of an ion-pair to improve the colon permeability of a low permeability drug: Atenolol. <i>European Journal of Pharmaceutical Sciences</i> , 2016, 93, 334-340.	1.9	17
57	Assessment of the Regulatory Methods for the Comparison of Highly Variable Dissolution Profiles. <i>AAPS Journal</i> , 2016, 18, 1550-1561.	2.2	18
58	Population pharmacokinetic model of lithium and drug compliance assessment. <i>European Neuropsychopharmacology</i> , 2016, 26, 1868-1876.	0.3	8
59	Intestinal Permeability of β^2 -Lapachone and Its Cyclodextrin Complexes and Physical Mixtures. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2016, 41, 795-806.	0.6	7
60	Exploring different strategies for imbalanced ADME data problem: case study on Caco-2 permeability modeling. <i>Molecular Diversity</i> , 2016, 20, 93-109.	2.1	11
61	The Fate of Patients with Solitary Pulmonary Nodules: Clinical Management and Radiation Exposure Associated. <i>PLoS ONE</i> , 2016, 11, e0158458.	1.1	4
62	Permeability Study of Polyphenols Derived from a Phenolic-Enriched Hibiscus sabdariffa Extract by UHPLC-ESI-UHR-Qq-TOF-MS. <i>International Journal of Molecular Sciences</i> , 2015, 16, 18396-18411.	1.8	28
63	Lung cancer risk and cancer-specific mortality in subjects undergoing routine imaging test when stratified with and without identified lung nodule on imaging study. <i>European Radiology</i> , 2015, 25, 3518-3527.	2.3	10
64	In-situ intestinal rat perfusions for human Fabs prediction and BCS permeability class determination: Investigation of the single-pass vs. the Doluisio experimental approaches. <i>International Journal of Pharmaceutics</i> , 2015, 480, 1-7.	2.6	63
65	Cyclometalated Iminophosphorane Gold(III) and Platinum(II) Complexes. A Highly Permeable Cationic Platinum(II) Compound with Promising Anticancer Properties. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 5825-5841.	2.9	88
66	Validation of a semi-physiological model for caffeine in healthy subjects and cirrhotic patients. <i>European Journal of Pharmaceutical Sciences</i> , 2015, 73, 57-63.	1.9	2
67	Semi-physiologic model validation and bioequivalence trials simulation to select the best analyte for acetylsalicylic acid. <i>European Journal of Pharmaceutical Sciences</i> , 2015, 74, 86-94.	1.9	6
68	In Situ Perfusion Model in Rat Colon for Drug Absorption Studies: Comparison with Small Intestine and Caco-2 Cell Model. <i>Journal of Pharmaceutical Sciences</i> , 2015, 104, 3136-3145.	1.6	57
69	Investigating the Discriminatory Power of BCS-Biowaiver <i>in Vitro</i> Methodology to Detect Bioavailability Differences between Immediate Release Products Containing a Class I Drug. <i>Molecular Pharmaceutics</i> , 2015, 12, 3167-3174.	2.3	26
70	Drug gastrointestinal absorption in rat: Strain and gender differences. <i>European Journal of Pharmaceutical Sciences</i> , 2015, 78, 198-203.	1.9	15
71	Tubulin acetylation promoting potency and absorption efficacy of deacetylase inhibitors. <i>British Journal of Pharmacology</i> , 2015, 172, 829-840.	2.7	17
72	Variability of permeability estimation from different protocols of subculture and transport experiments in cell monolayers. <i>Journal of Pharmacological and Toxicological Methods</i> , 2015, 71, 21-32.	0.3	31

#	ARTICLE	IF	CITATIONS
73	Management of patients with incidental findings in imaging tests: a large prospective single-center study. <i>Clinical Imaging</i> , 2014, 38, 249-254.	0.8	12
74	A promising camptothecin derivative: Semisynthesis, antitumor activity and intestinal permeability. <i>European Journal of Medicinal Chemistry</i> , 2014, 83, 366-373.	2.6	22
75	Modified Nonsink Equation for Permeability Estimation in Cell Monolayers: Comparison with Standard Methods. <i>Molecular Pharmaceutics</i> , 2014, 11, 1403-1414.	2.3	18
76	Validation of phenol red versus gravimetric method for water reabsorption correction and study of gender differences in Doluisio's absorption technique. <i>European Journal of Pharmaceutical Sciences</i> , 2014, 62, 105-110.	1.9	23
77	Mathematical modeling of oral absorption and bioavailability of a fluoroquinolone after its precipitation in the gastrointestinal tract. <i>Xenobiotica</i> , 2013, 43, 745-754.	0.5	5
78	Innovative in Vitro Method To Predict Rate and Extent of Drug Delivery to the Brain across the Blood-Brain Barrier. <i>Molecular Pharmaceutics</i> , 2013, 10, 3822-3831.	2.3	19
79	Ion-pair strategy for enabling amifostine oral absorption: Rat in situ and in vivo experiments. <i>European Journal of Pharmaceutical Sciences</i> , 2013, 49, 499-504.	1.9	28
80	Hydrogels: an interesting strategy for smart drug delivery. <i>Therapeutic Delivery</i> , 2013, 4, 157-160.	1.2	22
81	The Use of Rule-Based and QSPR Approaches in ADME Profiling: A Case Study on Caco-2 Permeability. <i>Molecular Informatics</i> , 2013, 32, 459-479.	1.4	42
82	Provisional Classification and <i>in Silico</i> Study of Biopharmaceutical System Based on Caco-2 Cell Permeability and Dose Number. <i>Molecular Pharmaceutics</i> , 2013, 10, 2445-2461.	2.3	78
83	Semisynthesis, Cytotoxic Activity, and Oral Availability of New Lipophilic 9-Substituted Camptothecin Derivatives. <i>ACS Medicinal Chemistry Letters</i> , 2013, 4, 651-655.	1.3	17
84	QSPR in Oral Bioavailability: Specificity or Integrality?. <i>Mini-Reviews in Medicinal Chemistry</i> , 2012, 12, 534-550.	1.1	20
85	A new mathematical approach for the estimation of the AUC and its variability under different experimental designs in preclinical studies. <i>Pharmaceutical Statistics</i> , 2012, 11, 14-23.	0.7	5
86	In vitro-in situ permeability and dissolution of fexofenadine with kinetic modeling in the presence of sodium dodecyl sulfate. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2012, 37, 65-75.	0.6	15
87	Influence of polyunsaturated fatty acids on Cortisol transport through MDCK and MDCK-MDR1 cells as blood-brain barrier in vitro model. <i>European Journal of Pharmaceutical Sciences</i> , 2011, 42, 290-299.	1.9	29
88	In Silico Prediction of Caco-2 Cell Permeability by a Classification QSAR Approach. <i>Molecular Informatics</i> , 2011, 30, 376-385.	1.4	76
89	Computer simulations for bioequivalence trials: Selection of analyte in BCS drugs with first-pass metabolism and two metabolic pathways. <i>European Journal of Pharmaceutical Sciences</i> , 2010, 41, 716-728.	1.9	14
90	An Exploratory Study of Two Caco-2 Cell Models for Oral Absorption: A Report on Their Within-laboratory and Between-laboratory Variability, and Their Predictive Capacity. <i>ATLA Alternatives To Laboratory Animals</i> , 2010, 38, 367-386.	0.7	23

#	ARTICLE	IF	CITATIONS
91	Unexpected findings at imaging: Predicting frequency in various types of studies. <i>European Journal of Radiology</i> , 2010, 74, 269-274.	1.2	21
92	Drug penetration across the blood-brain barrier: an overview. <i>Therapeutic Delivery</i> , 2010, 1, 535-562.	1.2	24
93	Computer simulations of bioequivalence trials: Selection of design and analyte in BCS drugs with first-pass hepatic metabolism: Linear kinetics (I). <i>European Journal of Pharmaceutical Sciences</i> , 2009, 36, 137-146.	1.9	22
94	Unique pharmacology of KAR-2, a potential anti-cancer agent: Absorption modelling and selective mitotic spindle targeting. <i>European Journal of Pharmaceutical Sciences</i> , 2009, 36, 11-19.	1.9	8
95	Computer simulations of bioequivalence trials: Selection of design and analyte in BCS drugs with first-pass hepatic metabolism: Part II. Non-linear kinetics. <i>European Journal of Pharmaceutical Sciences</i> , 2009, 36, 147-156.	1.9	18
96	Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Aciclovir. <i>Journal of Pharmaceutical Sciences</i> , 2008, 97, 5061-5073.	1.6	79
97	Three weeks release BCNU loaded hydrophilic-PLGA microspheres for interstitial chemotherapy: Development and activity against human glioblastoma cells. <i>Journal of Microencapsulation</i> , 2008, 25, 561-568.	1.2	15
98	Progress in the development of early diagnosis and a drug with unique pharmacology to improve cancer therapy. <i>Philosophical Transactions Series A, Mathematical, Physical, and Engineering Sciences</i> , 2008, 366, 3599-3617.	1.6	13
99	In situ kinetic modelling of intestinal efflux in rats: functional characterization of segmental differences and correlation within vitro results. <i>Biopharmaceutics and Drug Disposition</i> , 2007, 28, 229-239.	1.1	29
100	A topological substructural approach for the prediction of P-glycoprotein substrates. <i>Journal of Pharmaceutical Sciences</i> , 2006, 95, 589-606.	1.6	53
101	Kinetic modelling of passive transport and active efflux of a fluoroquinolone across Caco-2 cells using a compartmental approach in NONMEM. <i>Xenobiotica</i> , 2005, 35, 1067-1088.	0.5	35
102	Kinetic modelling of the intestinal transport of sarafloxacin. Studies in situ in rat and in vitro in Caco-2 cells. <i>Journal of Drug Targeting</i> , 2005, 13, 199-212.	2.1	23
103	PAMPA—a drug absorption in vitro model. <i>European Journal of Pharmaceutical Sciences</i> , 2004, 21, 429-441.	1.9	187
104	A topological-substructural molecular design (TOPS-MODE) approach to determining pharmacokinetics and pharmacological properties of 6-fluoroquinolone derivatives. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2003, 56, 197-206.	2.0	16
105	How and Where Are Drugs Absorbed?. , 0, , 249-280.		3